Meissa Vaccines is a start-up pharmaceutical company focused on advancement of innovative vaccines for respiratory syncytial virus (RSV), rhinovirus (common cold virus), and related viruses. Our core technology  involves novel methods in the genetic engineering of viruses and can be applied to multiple pathogens.

Our passion is child health, but our vaccine programs have the potential to benefit multiple age and population groups. Successful vaccines for RSV and rhinovirus would have widespread benefits for society and families. These include reducing the burden of serious lower respiratory tract disease in infants, reducing colds, reducing asthma and COPD exacerbations, and alleviating missed school and work.